Appropriate Patient Selection for Patients with HER2+ Metastatic Colorectal Cancer for Anti-HER2 Therapies

Video

Dr Tanios Bekaii-Saab describes for which patient groups he would use anti-HER2 therapies as a second-line treatment for HER2+ metastatic colorectal cancer.

Recent Videos
4 experts in this video
4 experts in this video
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
5 experts in this video
4 experts in this video
5 experts in this video
4 experts in this video
5 experts in this video
Related Content